Cannasat Therapeutics Strengthens its Board of Directors
Marketwire, January 11, 2022
TORONTO – Cannasat Therapeutics Inc. (CTH: TSX-V), a specialty clinical development pharmaceutical company targeting diseases of the brain, announced today that Ron Hosking has joined its Board of Directors as an independent director. Mr. Hosking replaces Peter Palframan, who is stepping down to focus on other professional obligations.
“Ron Hosking is an experienced biotech executive who brings to Cannasat significant experience in drug discovery, new product development and financial management. This nomination is occurring at a very exciting time in the life of the Company as Cannasat is evolving to a broader CNS clinical development company,” stated Dr. David Pattenden, Chairman of Cannasat. “I also want to thank Mr. Palframan for his dedication and contribution to our success since 2006. We wish Peter the best of luck in his future endeavours.”
Commenting on his appointment, Mr. Hosking said, “I am very pleased to join the board of Cannasat Therapeutics. Cannasat is a very exciting company which I believe will play a leading role in the development of exciting new CNS drug candidates.”
The number of Directors of the Company remains fixed at the maximum number of eight (8), and includes the following members: David Hill, Ron Hosking, Dr. Julia Levy, Dr. David Pattenden (Chairman), Dr. Alan Ryley, Rochelle Stenzler, Alan Torrie and Donald Ziraldo.
About Ron Hosking
Ron Hosking is a Chartered Accountant and currently the CFO at PlantForm Corporation. Ron was previously Vice President Finance & CFO of PreMD Inc., a public company in the life sciences sector that traded on both the TSX and AMEX. Ron has been in the biotech and medical device industries for over 25 years, with both private and public companies. His broad experience includes investor relations, equity and debt financings and licensing of technologies. He has also been actively involved in senior roles in trade and professional associations throughout his career.
About Cannasat Therapeutics
Cannasat is a specialty clinical development pharmaceutical company targeting diseases of the brain. Cannasat has a proprietary formulation technology for cannabinoid drug candidates, which may be used to treat neuropathic pain associated with multiple sclerosis and cancer, as well as for nausea/vomiting and appetite stimulation. Cannasat's strategy is to grow its portfolio of drug candidates through in-licensing and acquisitions, and to advance projects to Phase 2 proof-of-concept clinical studies. Once the drug candidates are sufficiently derisked, Cannasat intends to out-license the programs to the appropriate Pharma marketing partners for a combination of upfront, milestone, and royalty payments. More information about Cannasat (CTH: TSX-V) is available at www.cannasat.com.
Contact Information
Cannasat Therapeutics Inc.
Andrew Williams
COO & CFO
W: (416) 703-2449 (Ext. 253)
F: (416) 703-8752
[email protected]
www.cannasat.com
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility for the adequacy or accuracy of this press release.
